Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events.

Front Pharmacol · 2024 · PMC11260617 · PMID 39040467

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Corresponding to the signal intensity for weight loss poor of GLP-1 RAs in our study, a network meta-analysis showed a decreasing trend in weight loss efficacy for tirzepatide, semaglutide, and liraglutide ( Pan et al., 2024 ).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.